Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/nanjing-leads-biolabs-co-ltd" target="_blank" data-smartkarma-citation="entities:44126:1" rel="noopener">Nanjing Leads Biolabs (NLB HK)</a> entered into an exclusive global license agreement with Dianthus Therapeutics to jointly advance LBL-047, a first and potentially best-in-class pre-clinical asset.</li>
<li>Leads Biolabs will receive upfront and potential near-term milestone payments up to $38M and an additional $962M in total development and regulatory approval milestones and sales-based milestones across multiple indications.</li>
<li>Promising autoimmune drug candidate and sufficient cash runway make Dianthus a suitable outlicensing partner for Leads Biolabs. Since LBL-047 is a pre-clinical asset, the upfront payment seems competitive. </li>
</ul>



Nanjing Leads Biolabs (NLB HK) entered into an exclusive global license agreement with Dianthus Therapeutics to jointly advance LBL-047, a first and potentially best-in-class pre-clinical asset.
Leads Biolabs will receive upfront and potential near-term milestone payments up to $38M and an additional $962M in total development and regulatory approval milestones and sales-based milestones across multiple indications.
Promising autoimmune drug candidate and sufficient cash runway make Dianthus a suitable outlicensing partner for Leads Biolabs. Since LBL-047 is a pre-clinical asset, the upfront payment seems competitive. 


Nanjing Leads Biolabs (NLB HK): Bags Outlicensing Deal for Pre-Clinical Drug Candidate

Thematic (Sector/Industry)

<ul>
<li>CSPC Pharmaceutical’s Phase 3 trial of depression drug candidate HA1406 met pre-specified primary efficacy endpoint. Jiangsu Hengrui Pharmaceuticals received NMPA approval for long-acting basal insulin, sudelidec injection.</li>
<li>Otsuka Holdings secured FDA approval for Simtriyo, a once-daily extended-release capsule for ADHD. Nippon Shinyaku obtained exclusive commercialization rights for Tadekinig alfa in the U.S. for Hyperinflammatory Syndrome.</li>
<li>Pharmaessentia announced topline results from the Phase 1b clinical trial of P1101 (Besremi) and anti-PD1 in Chronic Hepatitis B or D. Cipla secured FDA approval for generic Advair Diskus.</li>
</ul>


CSPC Pharmaceutical’s Phase 3 trial of depression drug candidate HA1406 met pre-specified primary efficacy endpoint. Jiangsu Hengrui Pharmaceuticals received NMPA approval for long-acting basal insulin, sudelidec injection.
Otsuka Holdings secured FDA approval for Simtriyo, a once-daily extended-release capsule for ADHD. Nippon Shinyaku obtained exclusive commercialization rights for Tadekinig alfa in the U.S. for Hyperinflammatory Syndrome.
Pharmaessentia announced topline results from the Phase 1b clinical trial of P1101 (Besremi) and anti-PD1 in Chronic Hepatitis B or D. Cipla secured FDA approval for generic Advair Diskus.


APAC Healthcare Weekly (August 2) – CSPC, Hengrui, Otsuka, Nippon Shinyaku, PharmaEssnetia, Cipla

<ul>
<li>Sino Biopharmaceutical entered outlicensing deal with AstraZeneca for respiratory drug candidate TQC3721. Hansoh Pharmaceutical’s ADC drug candidate HS-20093 met primary endpoint of overall survival in Phase 3 trial for SCLC.</li>
<li>Wuxi Biologics’ Hebei drug substance manufacturing facility passed the Pre-License Inspection by the FDA. Astellas Pharma’s Padcev Keytruda combo was accepted for China review in perioperative muscle-invasive bladder cancer.</li>
<li>Otsuka’s Astex Pharmaceuticals inked R&amp;D deal with Genentech to identify small molecule breast cancer drug candidates. Celltrion’s Avastin biosimilar has secured formulary listings with two major PBMs in the U.S.</li>
</ul>


Sino Biopharmaceutical entered outlicensing deal with AstraZeneca for respiratory drug candidate TQC3721. Hansoh Pharmaceutical’s ADC drug candidate HS-20093 met primary endpoint of overall survival in Phase 3 trial for SCLC.
Wuxi Biologics’ Hebei drug substance manufacturing facility passed the Pre-License Inspection by the FDA. Astellas Pharma’s Padcev Keytruda combo was accepted for China review in perioperative muscle-invasive bladder cancer.
Otsuka’s Astex Pharmaceuticals inked R&amp;D deal with Genentech to identify small molecule breast cancer drug candidates. Celltrion’s Avastin biosimilar has secured formulary listings with two major PBMs in the U.S.


APAC Healthcare Weekly (July 12) – Sino Bio, Hansoh Pharma, Wuxi Bio, Astellas, Otsuka, Celltrion

Healthcare Analyst

Wilfred Yuen

<ul>
<li>We counted 5 license-out/collaboration deals this week: Antengene/K2 on TCE; Insilico/SK Bio on AI-enabled CNS drugs; Abbisko/Lilly on multiple targets; Haisco/Nuvectis on oncology/complement therapies; TrueLab/NewCo on two TL1A-targeting assets.</li>
<li>China approved 4 globally first-in-class therapies on 22 June: Biokin’s EGFR/HER3 ADC for nasopharyngeal carcinoma, CARsgen’s CLDN18.2 CAR-T for gastric cancer, CMS/Genrix’s silevimig for rabies, SBP/ProteLight’s peceleganan for wound infections.</li>
<li>Other news and updates include Hengrui, Ollin/Innovent, Sino Biopharm, Leads Biolabs, Everest, Ascletis.</li>
</ul>


We counted 5 license-out/collaboration deals this week: Antengene/K2 on TCE; Insilico/SK Bio on AI-enabled CNS drugs; Abbisko/Lilly on multiple targets; Haisco/Nuvectis on oncology/complement therapies; TrueLab/NewCo on two TL1A-targeting assets.
China approved 4 globally first-in-class therapies on 22 June: Biokin’s EGFR/HER3 ADC for nasopharyngeal carcinoma, CARsgen’s CLDN18.2 CAR-T for gastric cancer, CMS/Genrix’s silevimig for rabies, SBP/ProteLight’s peceleganan for wound infections.
Other news and updates include Hengrui, Ollin/Innovent, Sino Biopharm, Leads Biolabs, Everest, Ascletis.


China Healthcare Weekly Wrap (22-26 June)

<ul>
<li>Wuxi XDC partnered with Akari Therapeutics to accelerate IND filing for Akari’s ADC program. Xuanzhu Biopharmaceutical entered licensing agreement with Boston Oncology for upfront and milestone payments of $100M+.</li>
<li>Shionogi secured $119M BARDA contract for manufacturing, procurement, and expanded development of Fetroja for biothreat-related infections. ABL Bio’s partner has received Orphan Drug Designation from the FDA for tovecimig.</li>
<li>PharmaEssentia signed an investment agreement for a new manufacturing facility in Puerto Rico. Max Healthcare Institute is acquiring 58.4% stake in 250-bedded Kalinga Hospital for INR3B.</li>
</ul>


Wuxi XDC partnered with Akari Therapeutics to accelerate IND filing for Akari’s ADC program. Xuanzhu Biopharmaceutical entered licensing agreement with Boston Oncology for upfront and milestone payments of $100M+.
Shionogi secured $119M BARDA contract for manufacturing, procurement, and expanded development of Fetroja for biothreat-related infections. ABL Bio’s partner has received Orphan Drug Designation from the FDA for tovecimig.
PharmaEssentia signed an investment agreement for a new manufacturing facility in Puerto Rico. Max Healthcare Institute is acquiring 58.4% stake in 250-bedded Kalinga Hospital for INR3B.


APAC Healthcare Weekly (April 12) – Wuxi XDC, Xuanzhu Biopharma, Shionogi, ABL Bio, PharmaEssentia

China

Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for oncology, autoimmune, and other severe diseases, focusing on unmet medical needs. The company leverages proprietary technology platforms to advance a pipeline of drug candidates, including bispecific antibodies and fusion proteins. Founded in 2012, Leads Biolabs is headquartered in Nanjing, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Leads Biolabs (9887 HK)

Nanjing Leads Biolabs (NLB HK): Bags Outlicensing Deal for Pre-Clinical Drug Candidate

Leads Biolabs entered into an exclusive global license agreement with Dianthus Therapeutics to advance promising autoimmune drug candidate LBL-047,...

Tina Banerjee

APAC Healthcare Weekly (August 2) – CSPC, Hengrui, Otsuka, Nippon Shinyaku, PharmaEssnetia, Cipla

Hengrui got NMPA approval for long-acting insulin. FDA approves Otsuka’s new CNS drug. Pharmaessentia announced positive topline result from Phase...

Tina Banerjee

APAC Healthcare Weekly (July 12) – Sino Bio, Hansoh Pharma, Wuxi Bio, Astellas, Otsuka, Celltrion

Sino Bio stuck outlicensing deal with AstraZeneca. Hansoh’s ADC drug candidate met primary endpoint in Phase 3 trial. China will review Astellas’...

Tina Banerjee

China Healthcare Weekly Wrap (22-26 June)

This week saw 5 license-out/collaboration deals in the biopharma industry and China approving 4 globally first-in-class therapies, with updates...

Wilfred Yuen

APAC Healthcare Weekly (April 12) – Wuxi XDC, Xuanzhu Biopharma, Shionogi, ABL Bio, PharmaEssentia

Wuxi XDC inked deal with Akari Therapeutics. Xuanzhu Bio entered licensing deal with Boston Oncology. Shionogi secured $119M BARDA contract for...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Nanjing Leads Biolabs (NLB HK): Bags Outlicensing Deal for Pre-Clinical Drug Candidate

Leads Biolabs entered into an exclusive global license agreement with Dianthus Therapeutics to advance promising autoimmune drug candidate LBL-047,...

Tina Banerjee

APAC Healthcare Weekly (August 2) – CSPC, Hengrui, Otsuka, Nippon Shinyaku, PharmaEssnetia, Cipla

Hengrui got NMPA approval for long-acting insulin. FDA approves Otsuka’s new CNS drug. Pharmaessentia announced positive topline result from Phase...

Tina Banerjee

APAC Healthcare Weekly (July 12) – Sino Bio, Hansoh Pharma, Wuxi Bio, Astellas, Otsuka, Celltrion

Sino Bio stuck outlicensing deal with AstraZeneca. Hansoh’s ADC drug candidate met primary endpoint in Phase 3 trial. China will review Astellas’...

Tina Banerjee

China Healthcare Weekly Wrap (22-26 June)

​This week saw 5 license-out/collaboration deals in the biopharma industry and China approving 4 globally first-in-class therapies, with updates...

Wilfred Yuen

APAC Healthcare Weekly (April 12) – Wuxi XDC, Xuanzhu Biopharma, Shionogi, ABL Bio, PharmaEssentia

Wuxi XDC inked deal with Akari Therapeutics. Xuanzhu Bio entered licensing deal with Boston Oncology. Shionogi secured $119M BARDA contract for...

Tina Banerjee

This week saw 5 license-out/collaboration deals in the biopharma industry and China approving 4 globally first-in-class therapies, with updates...